The company's IPO comprises a fresh issue of equity shares worth up to Rs 760 crore and an Offer For Sale (OFS) of up to 2.34 crore equity shares aggregating Rs 1,082 crore, at the higher end of the price band, by selling shareholders. This takes the total IPO size to 1,842 crore.
The OFS would see sale of shares by existing investors CA Dawn Investments, a
At present, Nadathur Fareast Pte Ltd is the biggest shareholder in Indegene with a 23.64 per cent stake. CA Dawn Investments has a 20.42 per cent stake, and Brighton Park Capital owns a 12 per cent stake in the company.
Funds raised through the fresh issue would be used to pay debt, funding capital expenditure requirements, payment of deferred consideration for one of its past acquisitions, funding inorganic growth and general corporate purposes.
Indegene had raised USD 200 million from Carlyle Group and Brighton Park Capital in February 2021.
Founded in 1998, Indegene offers solutions that help enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales throughout their life cycle.
Kotak Mahindra Capital, Citigroup Global Markets India, J P Morgan India, Nomura Financial Advisory and Securities (India) are the book running lead managers to the issue.
SEE ALSO:
Upcoming smartphones launching in India in May 2024
Ultraviolette F77 Mach 2 electric sports bike launched in India starting at ₹2.99 lakh
Nothing Phone (2a) India-exclusive Blue Edition launched starting at ₹19,999